SS18L2

Across TCGA pan-cancer cohorts, SS18L2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of SS18L2’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where SS18L2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SS18L2 is over-expressed in tumor.

LSCC, HNSC, and LUAD are the cancer types where SS18L2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SS18L2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	II,III,IV	+0.485	<.001	8	view →
HNSC	Female	All	+0.300	.026	3	view →
LUAD	All	All	+0.202	.001	3	view →
CCRCC	All	All	+0.210	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

SS18L2–LSCC

Open the LSCC breakdown →